Managing T-DXd-Related Toxicity and Intolerance in Later-Line HER2+ Breast Cancer

The panel discussed the different ways to treat patients with HER2-positive metastatic breast cancer who also have brain metastases.

Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.

At an Around the Practice program in Charlotte, NC, experts spoke about the most recent research in multiple myeloma.

Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.

Expert panelists review key data from recent meetings on the management of multiple myeloma and consider how these can be applied to clinical practice.

Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.